Clinical Trials Logo

Validity and Safety clinical trials

View clinical trials related to Validity and Safety.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT04136015 Enrolling by invitation - Validity and Safety Clinical Trials

Early Conversion of Dasatinib in CML-CP Patients

Start date: October 22, 2019
Phase:
Study type: Observational

Chronic myeloid leukemia (CML) is a malignant disease of acquired hematopoietic stem cells. The BCR-ABL fusion gene is the pathogenic basis of CML. Tyrosine kinase inhibitors (TKIs) are targeted drugs for this fusion protein. With the wide clinical application of TKIs, the efficacy of CML patients has been greatly improved. However, there are still a significant number of patients who have poor response to the first generation of TKI drugs, imatinib, most of them have early molecular response failures (BCR-ABL(IS)>10% at 3 or 6 months) ,which means lower rates of molecular response, increased risk of progression, and higher overall survival. For them, the early conversion of dasatinib might be a better choice.